Cantor Fitzgerald Downgrades Entasis Therapeutics (NASDAQ:ETTX) to Neutral

Entasis Therapeutics (NASDAQ:ETTX – Get Rating) was downgraded by investment analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a report issued on Friday, The Fly reports.

Several other equities research analysts also recently commented on the stock. HC Wainwright downgraded shares of Entasis Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the company from $6.00 to $1.80 in a research report on Friday, March 4th. Zacks Investment Research downgraded shares of Entasis Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. Alliance Global Partners downgraded shares of Entasis Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, March 16th. Finally, Wedbush downgraded shares of Entasis Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $9.00 to $1.80 in a research report on Tuesday, March 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $3.15.

Shares of NASDAQ:ETTX opened at $1.89 on Friday. The stock has a market capitalization of $90.44 million, a price-to-earnings ratio of -1.69 and a beta of 1.45. Entasis Therapeutics has a 1-year low of $1.40 and a 1-year high of $3.88. The company has a 50 day moving average price of $1.84 and a 200 day moving average price of $2.12.

Entasis Therapeutics (NASDAQ:ETTX – Get Rating) last issued its earnings results on Wednesday, April 27th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.12). As a group, research analysts predict that Entasis Therapeutics will post -1.2 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in ETTX. Geode Capital Management LLC lifted its position in Entasis Therapeutics by 14.9% in the 3rd quarter. Geode Capital Management LLC now owns 93,168 shares of the company’s stock worth $311,000 after buying an additional 12,047 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in Entasis Therapeutics in the 3rd quarter worth approximately $87,000. Two Sigma Investments LP lifted its position in Entasis Therapeutics by 13.4% in the 3rd quarter. Two Sigma Investments LP now owns 186,230 shares of the company’s stock worth $622,000 after buying an additional 22,001 shares in the last quarter. Two Sigma Advisers LP lifted its position in Entasis Therapeutics by 40.5% in the 3rd quarter. Two Sigma Advisers LP now owns 229,000 shares of the company’s stock worth $765,000 after buying an additional 66,058 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in Entasis Therapeutics in the 3rd quarter worth approximately $107,000. Institutional investors own 6.91% of the company’s stock.

About Entasis Therapeutics (Get Rating)

Entasis Therapeutics Holdings Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii.

Further Reading